Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review

Pinzani, V�ronique; Bressolle, Fran�oise; Haug, Inger Johanne; Galtier, M.; Blayac, Jean Pierre; Balm�s, Pierre

doi:10.1007/s002800050185

Cited by 58 publications

(66 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When cisplatin was first approved for commercial use in 1978, the major toxicities were severe nausea and vomiting and a high incidence of renal dysfunction. Although these adverse effects are still of concern, they can be significantly reduced by the use of 5HT 3 -receptor antagonists and vigorous hydration (Pinzani et al, 1994). Administration of cisplatin in hypertonic saline may further alleviate nephrotoxic side effects (Ozols et al, 1984).…”

mentioning

confidence: 99%

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

et al. 2003

View full text Add to dashboard Cite

In the present study we describe the toxicity of weekly high-dose (70 -85 mg m À2 ) cisplatin in 400 patients (203 men, 197 women; median age 54 years) with advanced solid tumours treated in the period 1990 -2001 who took part in phase I/II trials, investigating the feasibility and efficacy of weekly cisplatin alone, or in combination with paclitaxel or etoposide. Cisplatin was administered in 250 ml NaCl 3% over 3 h, for six intended administrations. The mean number of administrations was 5.3 (range, 1 -6 administrations).Reasons not to complete six cycles were disease progression (7.5%), haematological toxicity (9%), nephrotoxicity (7%), ototoxicity (2.5%), neurotoxicity (1%), gastrointestinal toxicity (1%), cardiovascular complications (0.5%) or a combination of reasons including noncompliance and patient's request (5.5%). Logistic regression analysis was used to evaluate baseline parameters for prognostic value regarding toxicity. Leukopenia correlated with etoposide cotreatment, and thrombocytopenia with cisplatin dose and prior (platinum-based) chemotherapy. Risk factors for nephrotoxicity were older age, female gender, smoking, hypoalbuminaemia and paclitaxel coadministration. Neurotoxicity 4grade 1 (11% of patients) was associated with prior chemotherapy and paclitaxel coadministration. Symptomatic hearing loss occurred in 15% with anaemia as the predisposing factor. We conclude that weekly highdose cisplatin administered in hypertonic saline is a feasible treatment regimen.

show abstract

mentioning

confidence: 99%

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

et al. 2003

View full text Add to dashboard Cite

show abstract

“…6 Hence, cisplatin's clinical use is limited because of its severely toxic side effects, such as acute nephrotoxicity and chronic neurotoxicity. 7 Approaches to reduce these systemic side effects while retaining the potency of cisplatin have included embedding cisplatin in liposomes and micelles. 8,9 Moreover, targeting the drug to the disease site is an essential issue in the development of effective drug-delivery carriers.…”

Section: Introductionmentioning

confidence: 99%

Hyaluronan–cisplatin conjugate nanoparticles embedded in Eudragit S100-coated pectin/alginate microbeads for colon drug delivery

Tsai¹,

Yu²,

Tsao³

et al. 2013

IJN

View full text Add to dashboard Cite

Hyaluronan-cisplatin conjugate nanoparticles (HCNPs) were chosen as colon-targeting drug-delivery carriers due to the observation that a variety of malignant tumors overexpress hyaluronan receptors. HCNPs were prepared by mixing cisplatin with a hyaluronan solution, followed by dialysis to remove trace elements. The cells treated with HCNPs showed significantly lower viability than those treated with cisplatin alone. HCNPs were entrapped in Eudragit S100-coated pectinate/alginate microbeads (PAMs) by using an electrospray method and a polyelectrolyte multilayer-coating technique in aqueous solution. The release profile of HCNPs from Eudragit S100-coated HCNP-PAMs was pH-dependent. The percentage of 24-hour drug release was approximately 25.1% and 39.7% in pH 1.2 and pH 4.5 media, respectively. However, the percentage of drug released quickly rose to 75.6% at pH 7.4. Moreover, the result of an in vivo nephrotoxicity study demonstrated that Eudragit S100-coated HCNP-PAMs treatment could mitigate the nephrotoxicity that resulted from cisplatin. From these results, it can be concluded that Eudragit S100-coated HCNP-PAMs are promising carriers for colonspecific drug delivery.

show abstract

“…Cis-diammineplatinum(II) dichloride (cisplatin) is a potent anticancer drug used in cancer chemotherapy (McKeage 2005;Rosenberg et al 1969;Wong and Giandomenico 1999) but it can cause acute nephrotoxicity, and chronic neurotoxicity, and other toxicity (Lajer and Daugaard 1999;Pinzani et al 1994). In addition, cancer cells are either inherently refractory or can quickly acquire resistance to the drug (Fuertes, Alonso, and Perez 2003;Perez 1998).…”

mentioning

confidence: 99%

Degradable Cisplatin-Releasing Core-Shell Nanogels from Zwitterionic Poly(β -Aminoester)-Graft-PEG for Cancer Chemotherapy

Jin

Zhan

et al. 2007

Drug Delivery

View full text Add to dashboard Cite

Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review

Cited by 58 publications

References 0 publications

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

Hyaluronan–cisplatin conjugate nanoparticles embedded in Eudragit S100-coated pectin/alginate microbeads for colon drug delivery

Degradable Cisplatin-Releasing Core-Shell Nanogels from Zwitterionic Poly(β -Aminoester)-Graft-PEG for Cancer Chemotherapy

Contact Info

Product

Resources

About

Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review

Cited by 58 publications

References 0 publications

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

Hyaluronan&ndash;cisplatin conjugate nanoparticles embedded in Eudragit S100-coated pectin/alginate microbeads for colon drug delivery

Degradable Cisplatin-Releasing Core-Shell Nanogels from Zwitterionic Poly(β -Aminoester)-Graft-PEG for Cancer Chemotherapy

Contact Info

Product

Resources

About

Hyaluronan–cisplatin conjugate nanoparticles embedded in Eudragit S100-coated pectin/alginate microbeads for colon drug delivery